Dyspnea News and Research

RSS
Dyspnea or dyspnoea or shortness of breath is a debilitating symptom that is the experience of unpleasant or uncomfortable respiratory sensations.

Further Reading

Xeomin receives FDA approval for treatment of cervical dystonia

Xeomin receives FDA approval for treatment of cervical dystonia

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Pivotal PINNACLE trial results of VELCADE in patients with relapsed/refractory MCL released

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Pivotal Phase 3 IMPACT study results of PROVENGE published in New England Journal of Medicine

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports topline results from Phase 2b trial of FOLOTYN vs erlotinib in advanced NSCLC

Allos reports net loss of $20.0 million for second-quarter 2010

Allos reports net loss of $20.0 million for second-quarter 2010

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

Merck signs non-exclusive license agreement with LabCorp for commercialization of genetic test

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

FDA accepts to review sNDA for SPRYCEL for treating adult patients with CML

Research Roundup: 'Pay-for-performance' unintended effects; Lessons from Mass.; End of life treatment

Research Roundup: 'Pay-for-performance' unintended effects; Lessons from Mass.; End of life treatment

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Afinitor more than doubles progression-free survival in advanced pancreatic NET: Study

Clinical assessment study identifies opportunities to improve end-of-life care

Clinical assessment study identifies opportunities to improve end-of-life care

Japan's MHLW grants full marketing authorization to REVLIMID

Japan's MHLW grants full marketing authorization to REVLIMID

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Pfizer to discontinue commercial availability of Mylotarg for AML in U.S.

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

Alkermes receives tentative schedule notification for FDA advisory committee meeting on VIVITROL sNDA

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

FDA approves Jevtana in combination with prednisone for metastatic hormone-refractory prostate cancer

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

FDA grants Fast Track status for Genzyme's alemtuzumab development program for MS

New research evaluating substantial disease burden of PNH presented at European Hematology Association

New research evaluating substantial disease burden of PNH presented at European Hematology Association

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Phase III study of REVLIMID for treating patients with multiple myeloma shows improvement in PFS

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Data from Phase 1 study of FOLOTYN in patients with relapsed or refractory CTCL presented at EHA 2010

Phase II study results of riociguat for CTEPH and PAH published online

Phase II study results of riociguat for CTEPH and PAH published online

Clinical data from investigational study of patients with multiple myeloma presented at ASCO

Clinical data from investigational study of patients with multiple myeloma presented at ASCO